{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:16:51Z","timestamp":1771514211159,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Zhejiang Medical and Health Science and Technology","award":["2025KY246"],"award-info":[{"award-number":["2025KY246"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04623-w","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:15:35Z","timestamp":1769584535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between remnant cholesterol and cardiometabolic multimorbidity in non-alcoholic fatty liver disease patients: evidence from a cross-sectional study"],"prefix":"10.1186","volume":"26","author":[{"given":"Yilian","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinguo","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"4623_CR1","doi-asserted-by":"publisher","first-page":"e5205","DOI":"10.1136\/bmj.e5205","volume":"345","author":"SM Smith","year":"2012","unstructured":"Smith SM, Soubhi H, Fortin M, Hudon C, O\u2019Dowd T. Managing patients with multimorbidity: systematic review of interventions in primary care and community settings. BMJ. 2012;345:e5205. https:\/\/doi.org\/10.1136\/bmj.e5205.","journal-title":"BMJ"},{"key":"4623_CR2","doi-asserted-by":"publisher","unstructured":"Mendis S, Davis S, Norrving B. Organizational Update: The World Health Organization Global Status Report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke (2015) 46(5):e121\u20132. Epub 2015\/04\/16. https:\/\/doi.org\/10.1161\/strokeaha.115.008097.","DOI":"10.1161\/strokeaha.115.008097"},{"issue":"1","key":"4623_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","volume":"314","author":"E Di Angelantonio","year":"2015","unstructured":"Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52\u201360. https:\/\/doi.org\/10.1001\/jama.2015.7008.","journal-title":"JAMA"},{"key":"4623_CR4","doi-asserted-by":"publisher","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of ldl cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London, England) (2010) 376(9753):1670\u201381. Epub 2010\/11\/12. https:\/\/doi.org\/10.1016\/s0140-6736(10)61350-5.","DOI":"10.1016\/s0140-6736(10)61350-5"},{"issue":"9","key":"4623_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361. https:\/\/doi.org\/10.1016\/s2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4623_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2019.01.029","volume":"282","author":"RD Santos","year":"2019","unstructured":"Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis. 2019;282:110\u201320. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.01.029.","journal-title":"Atherosclerosis"},{"issue":"6","key":"4623_CR7","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/eurjpc\/zwab212","volume":"29","author":"L Alon","year":"2022","unstructured":"Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M, et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(6):938\u201346. https:\/\/doi.org\/10.1093\/eurjpc\/zwab212.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"4623_CR8","doi-asserted-by":"publisher","first-page":"101643","DOI":"10.1016\/j.cpcardiol.2023.101643","volume":"48","author":"G Bisaccia","year":"2023","unstructured":"Bisaccia G, Ricci F, Khanji MY, Sorella A, Melchiorre E, Iannetti G, et al. Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48(6):101643. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101643.","journal-title":"Curr Probl Cardiol"},{"key":"4623_CR9","doi-asserted-by":"publisher","unstructured":"Executive Summary of the Third Report of the National Cholesterol Education Program (Ncep) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Iii). Jama (2001) 285(19):2486\u201397. Epub 2001\/05\/23. https:\/\/doi.org\/10.1001\/jama.285.19.2486.","DOI":"10.1001\/jama.285.19.2486"},{"issue":"8","key":"4623_CR10","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.2337\/dci19-0036","volume":"43","author":"RB Goldberg","year":"2020","unstructured":"Goldberg RB, Stone NJ, Grundy SM. The 2018 Aha\/Acc\/Aacvpr\/Aapa\/Abc\/Acpm\/Ada\/Ags\/Apha\/Aspc\/Nla\/Pcna guidelines on the management of blood cholesterol in diabetes. Diabetes Care. 2020;43(8):1673\u20138. https:\/\/doi.org\/10.2337\/dci19-0036.","journal-title":"Diabetes Care"},{"issue":"3","key":"4623_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jama.298.3.299","volume":"298","author":"BG Nordestgaard","year":"2007","unstructured":"Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299\u2013308. https:\/\/doi.org\/10.1001\/jama.298.3.299.","journal-title":"JAMA"},{"issue":"1","key":"4623_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12933-023-01927-z","volume":"22","author":"B Guan","year":"2023","unstructured":"Guan B, Wang A, Xu H. Causal associations of remnant cholesterol with cardiometabolic diseases and risk factors: a mendelian randomization analysis. Cardiovasc Diabetol. 2023;22(1):207. https:\/\/doi.org\/10.1186\/s12933-023-01927-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"4623_CR13","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1038\/s41467-024-46686-x","volume":"15","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zhuang Z, Li Y, Xiao W, Song Z, Huang N, et al. Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic multimorbidity. Nat Commun. 2024;15(1):2451. https:\/\/doi.org\/10.1038\/s41467-024-46686-x.","journal-title":"Nat Commun"},{"issue":"7","key":"4623_CR14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41430-019-0413-1","volume":"73","author":"M Mazidi","year":"2019","unstructured":"Mazidi M, Huybrechts I, Kengne AP. Associations between serum lipophilic antioxidants levels and non-alcoholic fatty liver disease are moderated by adiposity. Eur J Clin Nutr. 2019;73(7):1088\u201390. https:\/\/doi.org\/10.1038\/s41430-019-0413-1.","journal-title":"Eur J Clin Nutr"},{"issue":"2","key":"4623_CR15","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1039\/d2fo02204d","volume":"14","author":"K Zhang","year":"2023","unstructured":"Zhang K, Nulali J, Zhang C, Chen Y, Cheng J, Shi X, et al. The association between serum vitamin A and NAFLD among US adults varied in different BMI groups: a cross-sectional study. Food Funct. 2023;14(2):836\u201344. https:\/\/doi.org\/10.1039\/d2fo02204d.","journal-title":"Food Funct"},{"issue":"1","key":"4623_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12944-024-02145-6","volume":"23","author":"P Xiao","year":"2024","unstructured":"Xiao P, Wang Z, Lu Z, Liu S, Huang C, Xu Y, et al. The association between remnant cholesterol and bone mineral density in Us adults: the national health and nutrition examination survey (Nhanes) 2013\u20132018. Lipids Health Dis. 2024;23(1):148. https:\/\/doi.org\/10.1186\/s12944-024-02145-6.","journal-title":"Lipids Health Dis"},{"key":"4623_CR17","doi-asserted-by":"publisher","first-page":"116556","DOI":"10.1016\/j.ecoenv.2024.116556","volume":"280","author":"A Zhang","year":"2024","unstructured":"Zhang A, Wei P, Ding L, Zhang H, Jiang Z, Mi L, et al. Associations of serum lead, cadmium, and mercury concentrations with all-cause and cause-specific mortality among individuals with cardiometabolic multimorbidity. Ecotoxicol Environ Saf. 2024;280:116556. https:\/\/doi.org\/10.1016\/j.ecoenv.2024.116556.","journal-title":"Ecotoxicol Environ Saf"},{"key":"4623_CR18","doi-asserted-by":"publisher","unstructured":"Jiang Z, Zhang S, Chen K, Wu Y, Zeng P, Wang T. Long-Term Influence of Air Pollutants on Morbidity and All-Cause Mortality of Cardiometabolic Multi-Morbidity: A Cohort Analysis of the Uk Biobank Participants. Environmental research (2023) 237(Pt 1):116873. Epub 2023\/08\/13. https:\/\/doi.org\/10.1016\/j.envres.2023.116873.","DOI":"10.1016\/j.envres.2023.116873"},{"key":"4623_CR19","doi-asserted-by":"publisher","unstructured":"Wang L, Li X, Wang Z, Bancks MP, Carnethon MR, Greenland P, et al. Trends in Prevalence of Diabetes and Control of Risk Factors in Diabetes among Us Adults, 1999\u20132018. Jama (2021) 326(8):1\u201313. Epub 2021\/06\/26. https:\/\/doi.org\/10.1001\/jama.2021.9883.","DOI":"10.1001\/jama.2021.9883"},{"issue":"4","key":"4623_CR20","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41440-023-01195-0","volume":"46","author":"JP Xu","year":"2023","unstructured":"Xu JP, Zeng RX, Zhang YZ, Lin SS, Tan JW, Zhu HY, et al. Systemic inflammation markers and the prevalence of hypertension: a NHANES cross-sectional study. Hypertens Res. 2023;46(4):1009\u201319. https:\/\/doi.org\/10.1038\/s41440-023-01195-0.","journal-title":"Hypertens Res"},{"key":"4623_CR21","doi-asserted-by":"publisher","unstructured":"Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2016) 22 Suppl 3:1\u2013203. Epub 2016\/05\/25. https:\/\/doi.org\/10.4158\/ep161365.gl.","DOI":"10.4158\/ep161365.gl"},{"issue":"2","key":"4623_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep4.1803","volume":"6","author":"P Rattan","year":"2022","unstructured":"Rattan P, Penrice DD, Ahn JC, Ferrer A, Patnaik M, Shah VH, et al. Inverse association of telomere length with liver disease and mortality in the Us population. Hepatol Commun. 2022;6(2):399\u2013410. https:\/\/doi.org\/10.1002\/hep4.1803.","journal-title":"Hepatol Commun"},{"issue":"6","key":"4623_CR23","doi-asserted-by":"publisher","first-page":"e1438","DOI":"10.1016\/j.cgh.2021.06.029","volume":"20","author":"D Kim","year":"2022","unstructured":"Kim D, Konyn P, Cholankeril G, Ahmed A. Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by Fibroscan. Clin Gastroenterol Hepatol. 2022;20(6):e1438\u201355. https:\/\/doi.org\/10.1016\/j.cgh.2021.06.029.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4623_CR24","doi-asserted-by":"crossref","unstructured":"Third Report of the National Cholesterol Education Program (Ncep) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Iii) Final Report. Circulation (2002) 106(25):3143\u2013421. Epub 2002\/12\/18.","DOI":"10.1161\/circ.106.25.3143"},{"issue":"1","key":"4623_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/apt.13012","volume":"41","author":"CE Ruhl","year":"2015","unstructured":"Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2015;41(1):65\u201376. https:\/\/doi.org\/10.1111\/apt.13012.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"4623_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","volume":"41","author":"J Lee","year":"2021","unstructured":"Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, et al. Prognostic accuracy of Fib-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int. 2021;41(2):261\u201370. https:\/\/doi.org\/10.1111\/liv.14669.","journal-title":"Liver Int"},{"issue":"10","key":"4623_CR27","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104\u201312. https:\/\/doi.org\/10.1016\/j.cgh.2009.05.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4623_CR28","doi-asserted-by":"publisher","unstructured":"Tsou P, Wu CJ. Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects. Journal of clinical medicine (2019) 8(7). Epub 2019\/07\/25. https:\/\/doi.org\/10.3390\/jcm8071057","DOI":"10.3390\/jcm8071057"},{"issue":"1","key":"4623_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of Mafld with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab. 2022;107(1):88\u201397. https:\/\/doi.org\/10.1210\/clinem\/dgab641.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"4623_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589\u2013600. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.013.","journal-title":"J Hepatol"},{"key":"4623_CR31","doi-asserted-by":"publisher","unstructured":"Toh JZK, Pan XH, Tay PWL, Ng CH, Yong JN, Xiao J, et al. A Meta-Analysis on the Global Prevalence, Risk Factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022) 20(11):2462\u201373.e10. Epub 2021\/09\/25. https:\/\/doi.org\/10.1016\/j.cgh.2021.09.021.","DOI":"10.1016\/j.cgh.2021.09.021"},{"issue":"1","key":"4623_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/strokeaha.120.030433","volume":"52","author":"J Xu","year":"2021","unstructured":"Xu J, Dai L, Zhang Y, Wang A, Li H, Wang Y, et al. Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events. Stroke. 2021;52(1):103\u201310. https:\/\/doi.org\/10.1161\/strokeaha.120.030433.","journal-title":"Stroke"},{"key":"4623_CR33","doi-asserted-by":"publisher","unstructured":"Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, et al. Endothelial Dysfunction and Cardiovascular Risk Profile in Nonalcoholic Fatty Liver Disease. Hepatology (Baltimore, Md) (2005) 42(2):473\u201380. Epub 2005\/06\/28. https:\/\/doi.org\/10.1002\/hep.20781.","DOI":"10.1002\/hep.20781"},{"key":"4623_CR34","doi-asserted-by":"publisher","unstructured":"Pastore A, Alisi A, di Giovamberardino G, Crudele A, Ceccarelli S, Panera N, et al. Plasma Levels of Homocysteine and Cysteine Increased in Pediatric Nafld and Strongly Correlated with Severity of Liver Damage. International journal of molecular sciences (2014) 15(11):21202\u201314. Epub 2014\/11\/20. https:\/\/doi.org\/10.3390\/ijms151121202.","DOI":"10.3390\/ijms151121202"},{"key":"4623_CR35","doi-asserted-by":"publisher","unstructured":"Racanelli V, Rehermann B. The Liver as an Immunological Organ. Hepatology (Baltimore, Md) (2006) 43(2 Suppl 1):S54\u201362. Epub 2006\/02\/01. https:\/\/doi.org\/10.1002\/hep.21060.","DOI":"10.1002\/hep.21060"},{"issue":"15","key":"4623_CR36","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.clinbiochem.2013.05.070","volume":"46","author":"L Stoner","year":"2013","unstructured":"Stoner L, Lucero AA, Palmer BR, Jones LM, Young JM, Faulkner J. Inflammatory biomarkers for predicting cardiovascular disease. Clin Biochem. 2013;46(15):1353\u201371. https:\/\/doi.org\/10.1016\/j.clinbiochem.2013.05.070.","journal-title":"Clin Biochem"},{"issue":"9","key":"4623_CR37","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1007\/s10620-009-1075-y","volume":"55","author":"N Alkhouri","year":"2010","unstructured":"Alkhouri N, Tamimi TA, Yerian L, Lopez R, Zein NN, Feldstein AE. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci. 2010;55(9):2644\u201350. https:\/\/doi.org\/10.1007\/s10620-009-1075-y.","journal-title":"Dig Dis Sci"},{"key":"4623_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2015.10.009","volume":"82","author":"AB Ouweneel","year":"2016","unstructured":"Ouweneel AB, Van Eck M. Lipoproteins as modulators of atherothrombosis: from endothelial function to primary and secondary coagulation. Vasc Pharmacol. 2016;82:1\u201310. https:\/\/doi.org\/10.1016\/j.vph.2015.10.009.","journal-title":"Vasc Pharmacol"},{"issue":"1","key":"4623_CR39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","volume":"21","author":"XD Zhou","year":"2022","unstructured":"Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21(1):270. https:\/\/doi.org\/10.1186\/s12933-022-01697-0.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"4623_CR40","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1007\/s12072-021-10209-3","volume":"15","author":"JH Park","year":"2021","unstructured":"Park JH, Koo BK, Kim W, Kim WH. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease. Hepatol Int. 2021;15(5):1148\u201359. https:\/\/doi.org\/10.1007\/s12072-021-10209-3.","journal-title":"Hepatol Int"},{"key":"4623_CR41","doi-asserted-by":"publisher","unstructured":"Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes (2015) 6(13):1246\u201358. Epub 2015\/10\/16. https:\/\/doi.org\/10.4239\/wjd.v6.i13.1246.","DOI":"10.4239\/wjd.v6.i13.1246"},{"issue":"10","key":"4623_CR42","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.numecd.2022.06.016","volume":"32","author":"D Li","year":"2022","unstructured":"Li D, Wang L, Zhou Z, Song L, Chen S, Yang Y, et al. Role of socioeconomic, lifestyle, and clinical factors in the progression of cardiometabolic multimorbidity in China: a 10-year prospective cohort study. Nutr Metab Cardiovasc Dis. 2022;32(10):2383\u201391. https:\/\/doi.org\/10.1016\/j.numecd.2022.06.016.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"4623_CR43","doi-asserted-by":"publisher","first-page":"e024476","DOI":"10.1136\/bmjopen-2018-024476","volume":"9","author":"D Zhang","year":"2019","unstructured":"Zhang D, Tang X, Shen P, Si Y, Liu X, Xu Z, et al. Multimorbidity of cardiometabolic diseases: prevalence and risk for mortality from one million Chinese adults in a longitudinal cohort study. BMJ Open. 2019;9(3):e024476. https:\/\/doi.org\/10.1136\/bmjopen-2018-024476.","journal-title":"BMJ Open"},{"issue":"34","key":"4623_CR44","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1093\/eurheartj\/ehab413","volume":"42","author":"Y Han","year":"2021","unstructured":"Han Y, Hu Y, Yu C, Guo Y, Pei P, Yang L, et al. Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study. Eur Heart J. 2021;42(34):3374\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehab413.","journal-title":"Eur Heart J"},{"issue":"7","key":"4623_CR45","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/circulationaha.117.030898","volume":"137","author":"R Pazoki","year":"2018","unstructured":"Pazoki R, Dehghan A, Evangelou E, Warren H, Gao H, Caulfield M, et al. Genetic predisposition to high blood pressure and lifestyle factors: associations with midlife blood pressure levels and cardiovascular events. Circulation. 2018;137(7):653\u201361. https:\/\/doi.org\/10.1161\/circulationaha.117.030898.","journal-title":"Circulation"},{"issue":"1","key":"4623_CR46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12933-021-01434-z","volume":"20","author":"Z Song","year":"2021","unstructured":"Song Z, Yang R, Wang W, Huang N, Zhuang Z, Han Y, et al. Association of healthy lifestyle including a healthy sleep pattern with incident type 2 diabetes mellitus among individuals with hypertension. Cardiovasc Diabetol. 2021;20(1):239. https:\/\/doi.org\/10.1186\/s12933-021-01434-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"4623_CR47","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2012.08.1026.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"4623_CR48","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/ana.25432","volume":"85","author":"A Varbo","year":"2019","unstructured":"Varbo A, Nordestgaard BG. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population. Ann Neurol. 2019;85(4):550\u20139. https:\/\/doi.org\/10.1002\/ana.25432.","journal-title":"Ann Neurol"},{"issue":"5","key":"4623_CR49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2188\/jea.JE20200305","volume":"32","author":"S Si","year":"2022","unstructured":"Si S, Hou L, Chen X, Li W, Liu X, Liu C, et al. Exploring the causal roles of circulating remnant lipid profile on cardiovascular and cerebrovascular diseases: mendelian randomization study. J Epidemiol. 2022;32(5):205\u201314. https:\/\/doi.org\/10.2188\/jea.JE20200305.","journal-title":"J Epidemiol"},{"issue":"3","key":"4623_CR50","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/atvbaha.117.310473","volume":"38","author":"AB Wulff","year":"2018","unstructured":"Wulff AB, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Apoc3 loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk: mediation- and meta-analyses of 137 895 individuals. Arterioscler Thromb Vasc Biol. 2018;38(3):660\u20138. https:\/\/doi.org\/10.1161\/atvbaha.117.310473.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4623_CR51","doi-asserted-by":"publisher","unstructured":"Wu Y, Avcilar-K\u00fcc\u00fckg\u00f6ze I, Santovito D, Atzler D. Amino acid metabolism and autophagy in atherosclerotic cardiovascular disease. Biomolecules (2024) 14(12). Epub 20241206https:\/\/doi.org\/10.3390\/biom14121557","DOI":"10.3390\/biom14121557"},{"key":"4623_CR52","doi-asserted-by":"publisher","first-page":"1098078","DOI":"10.3389\/fendo.2023.1098078","volume":"14","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Zhang Q, Li H, Zhou G, Shi P, Zhang X, et al. Remnant cholesterol, stronger than triglycerides, is associated with incident non-alcoholic fatty liver disease. Front Endocrinol. 2023;14:1098078. https:\/\/doi.org\/10.3389\/fendo.2023.1098078.","journal-title":"Front Endocrinol"},{"key":"4623_CR53","doi-asserted-by":"publisher","unstructured":"Pastori D, Baratta F, Novo M, Cocomello N, Violi F, Angelico F, et al. Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. Journal of clinical medicine (2018) 7(11). Epub 2018\/10\/27. https:\/\/doi.org\/10.3390\/jcm7110378","DOI":"10.3390\/jcm7110378"},{"issue":"2","key":"4623_CR54","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1210\/er.2018-00184","volume":"40","author":"PB Sandesara","year":"2019","unstructured":"Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019;40(2):537\u201357. https:\/\/doi.org\/10.1210\/er.2018-00184.","journal-title":"Endocr Rev"},{"issue":"6","key":"4623_CR55","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/153537020422900611","volume":"229","author":"KV Batt","year":"2004","unstructured":"Batt KV, Avella M, Moore EH, Jackson B, Suckling KE, Botham KM. Differential effects of low-density lipoprotein and chylomicron remnants on lipid accumulation in human macrophages. Exp Biol Med (Maywood). 2004;229(6):528\u201337. https:\/\/doi.org\/10.1177\/153537020422900611.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"5","key":"4623_CR56","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/atvbaha.116.308834","volume":"37","author":"SJ Bernelot Moens","year":"2017","unstructured":"Bernelot Moens SJ, Verweij SL, Schnitzler JG, Stiekema LCA, Bos M, Langsted A, et al. Remnant cholesterol elicits arterial wall inflammation and a multilevel cellular immune response in humans. Arterioscler Thromb Vasc Biol. 2017;37(5):969\u201375. https:\/\/doi.org\/10.1161\/atvbaha.116.308834.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"4623_CR57","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jacc.2014.01.088","volume":"64","author":"DF van Wijk","year":"2014","unstructured":"van Wijk DF, Sjouke B, Figueroa A, Emami H, van der Valk FM, MacNabb MH, et al. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. J Am Coll Cardiol. 2014;64(14):1418\u201326. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.088.","journal-title":"J Am Coll Cardiol"},{"key":"4623_CR58","doi-asserted-by":"publisher","first-page":"104984","DOI":"10.1016\/j.phrs.2020.104984","volume":"159","author":"CH Zhang","year":"2020","unstructured":"Zhang CH, Zhou BG, Sheng JQ, Chen Y, Cao YQ, Chen C. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. Pharmacol Res. 2020;159:104984. https:\/\/doi.org\/10.1016\/j.phrs.2020.104984.","journal-title":"Pharmacol Res"},{"issue":"8","key":"4623_CR59","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1172\/jci86610","volume":"126","author":"PL Gordts","year":"2016","unstructured":"Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, et al. Apoc-III inhibits clearance of triglyceride-rich lipoproteins through Ldl family receptors. J Clin Invest. 2016;126(8):2855\u201366. https:\/\/doi.org\/10.1172\/jci86610.","journal-title":"J Clin Invest"},{"key":"4623_CR60","doi-asserted-by":"publisher","unstructured":"Siddiqui MS, Fuchs M, Idowu MO, Luketic VA, Boyett S, Sargeant C, et al. Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated with Atherogenic Lipoprotein Profile. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015) 13(5):1000\u20138.e3. Epub 2014\/10\/15. https:\/\/doi.org\/10.1016\/j.cgh.2014.10.008.","DOI":"10.1016\/j.cgh.2014.10.008"},{"issue":"2","key":"4623_CR61","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/01.cir.82.2.495","volume":"82","author":"MA Austin","year":"1990","unstructured":"Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82(2):495\u2013506. https:\/\/doi.org\/10.1161\/01.cir.82.2.495.","journal-title":"Circulation"},{"key":"4623_CR62","doi-asserted-by":"publisher","unstructured":"Cusi K. Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. Gastroenterology (2012) 142(4):711\u201325.e6. Epub 2012\/02\/14. https:\/\/doi.org\/10.1053\/j.gastro.2012.02.003.","DOI":"10.1053\/j.gastro.2012.02.003"},{"issue":"2","key":"4623_CR63","doi-asserted-by":"publisher","first-page":"101903","DOI":"10.1016\/j.aohep.2025.101903","volume":"30","author":"LA Diaz","year":"2025","unstructured":"Diaz LA, Arab JP, Idalsoaga F, Perelli J, Vega J, Dirchwolf M, et al. Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (Masld) by the Latin American Working Group. Ann Hepatol. 2025;30(2):101903. https:\/\/doi.org\/10.1016\/j.aohep.2025.101903.","journal-title":"Ann Hepatol"},{"issue":"5","key":"4623_CR64","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/hep.0000000000000670","volume":"79","author":"F Kanwal","year":"2024","unstructured":"Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology (Baltimore, MD). 2024;79(5):1212\u20139. https:\/\/doi.org\/10.1097\/hep.0000000000000670.","journal-title":"Hepatology (Baltimore, MD)"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04623-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:28:08Z","timestamp":1771511288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04623-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4623"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04623-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The National Center for Health Statistics (NCHS) Research Ethics Review Board approved the investigation protocol for NHANES and all study participants\u00a0signed an\u00a0informed\u00a0consent\u00a0term. The informed consent procedures for all participants are publicly available through the CDC.gov website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}